Motivation
Pat ients with longstanding type 1 diabetes mellitus have little or no endogenous insulin production, leaving the body unable to lower blood glucose (BG) levels without exogenous insulin. Technological advances have enabled the development of a closed-loop artificial pancreas, reducing the burden of glucose management for these patients. [1] [2] [3] Continuous glucose monitors measure subcutaneous glucose levels while pumps infuse insulin and/or glucagon subcutaneously. A controller then connects these two. While some investigators have proposed and tested controllers using pumps for both insulin and glucagon, 4 we focus on the more common approach using only an insulin pump.
In this study, we examined two fundamental challenges faced by any such closed-loop artificial pancreas and developed a novel controller to explicitly address these difficulties.
First, the acute and chronic risks of extreme blood glucose levels are asymmetric. 5 Low BG levels (hypoglycemia) are acutely risky as they can result in altered mental state, seizures, and coma. Meanwhile, high BG levels (hyperglycemia) increase the risk of chronic complications such as retinopathy, nephropathy, and cardiovascular disease. In the face of significant uncertainty, this asymmetry should cause a controller to err toward high BG levels. That is, controller behavior should vary with observed uncertainty.
Second, insulin action is irreversible. Using only insulin, the controller cannot actively counter the effects of delivered insulin. This means that a controller should be cautious to avoid slow recoveries from unexpected insulin overdoses. And again, the level of caution should vary with the level of uncertainty.
In this work, we extended model predictive control 6 as a basis for a closed-loop artificial pancreas. We explicitly managed the expected future risk to trade off the dangers of hypoglycemia and hyperglycemia. In the process, we explicitly considered uncertainty and the potential effects of future BG measurements and controller actions.
We began by analyzing the challenges of asymmetry and irreversible insulin. We then developed the novel extended model predictive controller (EMPC) that explicitly deals with these challenges. We finally demonstrated the improved performance of this controller on the University of Virginia/Padova (UVa/ Padova) Metabolic Simulator 7 against a proportionalintegral-derivative (PID) controller, a basic model predictive controller (MPC), and a published MPC algorithm. 8 
Asymmetric Risk
The ultimate objective of any BG controller is to minimize the complications resulting from poor BG control. To this end, we proposed incorporating an explicit estimate of risk into our feedback controller. We first discussed known approximations of the risk of diabetic complications versus BG level. Thereafter, we developed a continuous, convex function describing risk that is also suitable to the optimization needed in MPC. We then explored how asymmetric risk should affect control decisions.
Approximating the Risk of Complications
The Diabetes Complication and Control Trial (DCCT) 9 and the Epidemiology of Diabetes Interventions and Complications (EDIC) trial 10 show an increased risk of chronic complications with higher hemoglobin A1c (HbA1c) (glucose levels). They also describe the acute detrimental effects of hypoglycemia. While informative, they do not provide a single numerical metric of the risk of complications.
To provide a single risk metric combining chronic and acute elements, Kovatchev and colleagues 5, 11 symmetrized the distribution of BG levels. They assumed that less common BG levels are inherently more risky than more common BG levels. The resulting formula is R(g) = 10[1.509ln(g) 8, [12] [13] [14] [15] Continuity and convexity are also important since they make optimizations faster and more robust.
Clinical Risk Measure for Control
While there are ways to modify the existing risk functions to make them continuous and convex over the real numbers, we chose to generate a new simpler function based directly upon the DCCT and EDIC trials.
The chronic risk of retinopathy correlates roughly linearly with the HbA1c for values between 5.5 and 9.0 (about 111 to 212 mg/dl). 9 Because HbA1c correlates with mean BG values, 16 we could approximate the risks of chronic complications as a linear function of BG levels.
The acute risks of low BG levels increases sharply with dropping BG level starting with lethargy and mild hypoglycemia and progressing quickly to seizures and sever hypoglycemia. As there is no data to directly support a specific analytic expression, we chose a simple cubic model.
The risk function for control that combines hypoglycemic and hyperglycemic risks is then
and is parameterized by the constants a, b, c, and d. In practice, this expression could be adjusted parametrically or even functionally subject to clinical judgement or at a user's discretion.
To match the R'(g) function, discussed above, used in Magni and colleagues 8 
The Effects of Risk Asymmetry on Optimal Control
The risk of complications is asymmetric about the lowest risk glucose concentration of 140 mg/dl, 8 so that a glucose concentration of 190 mg/dl is much less risky than a glucose concentration of 90 mg/dl. Since future BG concentration values are never certain, controllers should always consider the possibility of values that become higher or lower than expected. This means that as the prediction uncertainty increases, less insulin should be delivered to bias BG levels to higher values where risk increases more gently. Figure 2 shows an illustrative example where shifting the range of possible future values upward lowers the average risk. Mathematically, this corresponds to minimizing the expected risk of the prediction distribution instead of minimizing the risk of the mean prediction. This is a significant effect since predictions for several hours into the future can easily have standard deviations of 40 to 100 mg/dl. The "Too risky" distribution (red) is positioned with its center at the minimum risk glucose concentration of 140 mg/dl. The "Minimally risky" distribution is positioned to minimize the expected risk of the uniform distribution. We chose uniform distributions for display only.
Irreversible Insulin
Predictions are inherently uncertain, hence controllers should consider how they will respond when the actual values end up above or below the predicted mean values. With the aid of future glucose measurements, higher than predicted mean values will be rejected by injecting more insulin. Lower than predicted values may be rejected by injecting less insulin provided that injecting less insulin does not mean removing already injected insulin. In that case, the controller can only rely on the endogenous glucose production (EGP) to slowly raise the glucose concentrations back to desirable levels, as shown in Figure 3 . Therefore, it is imperative that controllers understand how uncertain predictions are and not inject too much insulin too soon.
Extended Model Predictive Control
This section extends MPC in three steps to explicitly incorporate the risk of complications, prediction uncertainty, and future glucose measurements.
Basic MPC Framework
MPC chooses insulin infusions to optimize a cost function. 6 We denote u 0 as the insulin to be infused at the current time, 
where all infusions must fall below the pump limit U max .
Traditionally, cost functions are often quadratic and trade off glucose excursions with infusion rate changes. For example,
where J provides a weighting parameter for tuning controller aggressiveness.
Risk of Complications
To minimize the risk of complications, we replaced the traditional cost function with the average risk
for all predicted glucose concentrations. We generated the predictions using a published prediction algorithm that incorporates meal detection and estimation. 17 The adjusted optimization is
This change allowed us to minimize the risk but ignores both prediction uncertainty and future glucose measurements.
Prediction Uncertainty
In addition to the predicted future glucose concentrations g → , the prediction algorithm also supplies the estimated standard deviations s → of the predicted concentrations.
Assuming that the prediction errors are Gaussian, g To approximate the expected risk of the entire distribution of predictions, we calculated the average risk for five parallel predictions that span the full distribution. These five trajectories are g
where j ∈ [-2.5, -1.25, 0, 1.25, 2.5]. The average risk values for the five trajectories are summed according to their normalized probability P j . We omitted the constants and standard deviation terms in the calculation of P j as Figure 3 . Example of pump limited compensation for uncertainty.
At time "Now" the controller injects insulin and is then told at "Future measurement" whether the actual value was higher, at, or lower than the expected value (black Xs). The higher trajectory is rejected quickly by injecting more insulin. The lower value is corrected slowly by endogenous glucose production. 
j ∈ [-2.5, -1.25, 0, 1.25, 2.5]
We chose to approximate the full distribution of predictions by five potential trajectories as this provides minimal error for a reasonable computational cost.
Future Controller Actions
As we were now considering five potential future glucose trajectories, we realized that the controller would have to respond differently in the future based on which of these trajectories will come true. And while future measurements will resolve this multiplicity, until such measurements arrived we had to allow a multiplicity of future control actions. So we defined five parallel future control actions u 
Validation
We validated the performance of the EMPC on the UVa/Padova Metabolic Simulator. 7 The simulator is approved by the U.S. Food and Drug Administration as a substitute for animal trials using a population of 100 patients to model meals, glucose-insulin dynamics, and interpatient variability. The publicly available portion of the simulator includes only 10 adult patients who were chosen to span the full range of the 100 patients. Unfortunately, for such a small a number of patients this implies that these patients are not a typical distribution of patients. In particular, we believe patient 9 encodes an outlier case and is not representative of one tenth of patients. So while we show individual results for all 10 publicly available patients, we exclude patient 9 when averaging over the patient population. This is also detailed in Appendix A.
Each patient was simulated for 36 hours and was provided with six unannounced meals, lasting 20 minutes each and measuring 50 g CHO at 9 a.m., 70 g at 1 p.m., 90 g at 5:30 p.m., 25 g at 8 p.m., 50 g at 9 a.m., and 70 g at 1 p.m. This scenario matches a scenario used for a clinical trial, and further represents a worstcase scenario where the patient announces none of their meals. Research shows that adolescents routinely miss two meal boluses per week while using manual control. 18 We feared that the use of closed-loop control will worsen this behavior, making the worst-case scenario an important test.
The controllers used a sample time of 5 minutes, calculating a new insulin infusion every 5 minutes. Each infusion was limited to a U max of six units and predictions were carried out to a horizon of 60 samples or 300 minutes.
Controllers for Comparison
We provided three controllers for direct comparison to the EMPC results.
First, we created a basic PID controller that is fully described by u n = 6.375 × 10 -5 P n + basal + 0.0046D n P n = g n -140 (11)
The setpoint was chosen to match the lowest risk glucose value, 140 mg/dl. The integral term was locked to the basal rate to avoid windup issues associated with saturated inputs and sustained positive disturbances, such as meals. The weights for the proportional (6.375 × 10 -5 units per mg/dl) and derivative (0.0046 U per mg/dl) terms were optimized to minimize the average blood glucose risk index (BGRI) 8 on the 10 patients.
Second, we created an MPC using the cost function in Equation (6), where J = 300 was chosen to minimize the average BGRI on the 10 patients. to illuminate the benefits of the contributions of this article, isolated from the potential confounding effects of different prediction methods.
Lastly, we used an optimized BB control as a lower bound on the BGRI. 8 Specifically, the basal rate and one bolus at the start of each meal were optimized to provide the minimum possible BGRI. 8 The basal rate was chosen to cause a steady state value lower than the zero risk value of 140 mg/dl. This reduces the risk effect of meals, and suggests a slow recovery from the last meals in the day. Because so many parameters (basal rates and boluses) were tuned noncausally, on a patient-specific level and with full knowledge of meals, this served as a lower bound on the achievable BGRI. 
Results
These controllers caused different characteristic effects on the controlled BG level. The PID controller reacted slowly to meals allowing larger disturbances due to meals. On the other end, the BB control reacted immediately. Since the EMPC controller was not hampered by the objective weight on large insulin infusion rates, it rejected meal disturbances faster than the MPC controller but slower than the noncausal BB controller.
The EMPC and MPC both show dips in the BG value just before meals as a result of meal anticipation in the prediction between 6 a.m. and 10 p.m. Because the EMPC also uses uncertainty, it avoided the prebreakfast low that occurs for the MPC after 3 hours of anticipated but unrealized meals. Figure 4 shows the average BG levels across all valid patients. Appendix B shows the individual results for all simulated patients. Tables 1 and 2 provide the value of published performance measures. 5 The BGRI, low blood glucose index (LBGI), and high blood glucose index (HBGI) follow Magni and colleagues' definition used in the published results. 8 In Table 1 , we include the Student's t-test significance measure of the changes in the BGRI relative to EMPC. Comparing the EMPC to the PID, MPC, and BB controllers, the t-test assesses whether the two sets of nine BGRI values for the nine valid patients are likely to share the same mean.
Independent Validation
We also validated against the published results from an independently created MPC, 8 denoted by IMPC. The IMPC was tested on the private set of 100 adult simulator patients. The IMPC controller is advantaged 
Discussion
The EMPC controller has shown statistically significant performance benefits on the Metabolic Simulator, as measured by the BGRI. In comparison to the published MPC, 8 which differs both in prediction and control algorithm, the EMPC reduced the avoidable risk by 56%. In comparison to our MPC, which shares the same prediction algorithm, the EMPC lowered the avoidable risk by 30%.
These improvements can be traced to two general sources: the prediction algorithm and the control algorithm. With regard to prediction, we know that reduced BGRI correlates with a decreased premeal glucose level. This suggests a benefit from controlling more aggressively in advance of expected meals to help reduce the future meal effect. Indeed, the prediction algorithm used by both the MPC and EMPC anticipates meals, allowing the controllers to implicitly accomplish this. Testing of the EMPC controller with a worst-case missed dinner and evening snack shows a minimal downside for this benefit. In these tests, the glucose concentrations only dropped to a minimum of 84 mg/dl after the missed meals. A concentration of 84 mg/dl has the same BGRI as the hyperglycemic glucose value of 244 mg/dl.
The improvement due to the controller extensions presented in this article can be attributed to the incorporation of uncertainty and thereby the ability to pursue prediction horizons of 5 hours. Other MPC algorithms use maximum prediction horizons between 2 and 4 hours. 8, 14, 19, 20 Without evaluating uncertainty, each of those algorithms is forced to treat all predictions with the horizon as equally relevant. Our inclusion of uncertainty can implicitly reduce the weight given to the less certain, long-term predictions. This also allows us to adapt to the increased uncertainty around unannounced meals with unknown sizes.
We also believe the presented MPC extensions will prove robust in practice. The EMPC contains no tuning parameters or indirect weighting parameters. It simply allows the definition and adjustment of the risk function, Equation (3), which has direct clinical relevance.
Of course, the EMPC does leave room for improvement. In particular, we approximated the distribution of potential future glucose values by five distinct glucose trajectories. Other approximations using more trajectories or trajectories that branch further in the future are conceivable. With increasing computational power, it may be feasible and even beneficial to consider greater degrees of multiplicity.
Conclusions
By taking advantage of estimates of prediction uncertainty and understanding the asymmetries associated with the risks of complications and irreversible insulin action, we extended the MPC framework. The resultant, novel MPC-based controller lowers the avoidable risk by 56% relative to a published MPC algorithm when tested on a similar population. We hope and believe that with additional in silico and in vivo testing, these extensions and the controllers and products they enable will help alleviate the burden for type 1 diabetes patients. The following table provides the results individually for all ten patients. 
